Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR13113] to IKAP/p150
- Suitable for: WB, ICC/IF, Flow Cyt
- Reacts with: Human
Product nameAnti-IKAP/p150 antibody [EPR13113]
See all IKAP/p150 primary antibodies
DescriptionRabbit monoclonal [EPR13113] to IKAP/p150
Tested applicationsSuitable for: WB, ICC/IF, Flow Cytmore details
Unsuitable for: IHC-P or IP
Species reactivityReacts with: Human
Recombinant fragment within Human IKAP/p150. The exact sequence is proprietary.
Database link: O95163
- HepG2, HeLa, Jurkat and 293T cell lysates; HeLa cells; Jurkat cells.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product was previously labelled as IKAP
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab179437 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/10000 - 1/50000. Predicted molecular weight: 150 kDa.|
|ICC/IF||1/50 - 1/100.|
|Flow Cyt||1/10 - 1/50.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
FunctionMay act as a scaffold protein that may assemble active IKK-MAP3K14 complexes (IKKA, IKKB and MAP3K14/NIK).
Acts as subunit of the RNA polymerase II elongator complex, which is a histone acetyltransferase component of the RNA polymerase II (Pol II) holoenzyme and is involved in transcriptional elongation. Elongator may play a role in chromatin remodeling and is involved in acetylation of histones H3 and probably H4.
Involvement in diseaseDefects in IKBKAP are the cause of hereditary sensory and autonomic neuropathy type 3 (HSAN3) [MIM:223900]; also known as Riley-Day syndrome or familial dysautonomia (FD). This autosomal recessive disorder is due to the poor development and survival, and progressive degeneration of the sensory, sympathetic and parasympathetic neurons. HSAN3 individuals are affected with a variety of symptoms such as decreased sensitivity to pain and temperature, cardiovascular instability, recurrent pneumonias, vomiting crises, and gastrointestinal dysfunction. It is primarily confined to individuals of Ashkenazi Jewish descent, with an incidence of 1/3'600 live births.
Sequence similaritiesBelongs to the ELP1/IKA1 family.
Cellular localizationCytoplasm. Nucleus.
- Information by UniProt
- DKFZp781H1425 antibody
- DYS antibody
- Dysautonomia (Riley Day syndrome hereditary sensory autonomic neuropathy type III) antibody
All lanes : Anti-IKAP/p150 antibody [EPR13113] (ab179437) at 1/10000 dilution
Lane 1 : HepG2 cell lysate
Lane 2 : HeLa cell lysate
Lane 3 : Jurkat cell lysate
Lane 4 : 293T cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 150 kDa
Immunofluorescent analysis of HeLa cells labeling IKAP/p150 with ab179437 at 1/50 dilution (green). DAPI nuclear staining (blue).
Flow cytometric analysis of permeabilized Jurkat cells labeling IKAP/p150 with ab179437 at 1/10 dilution (red) compared to a rabbit IgG negative control (green).
ab179437 has been referenced in 2 publications.
- Morini E et al. ELP1 Splicing Correction Reverses Proprioceptive Sensory Loss in Familial Dysautonomia. Am J Hum Genet 104:638-650 (2019). PubMed: 30905397
- Xu S et al. Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer. Nat Commun 10:5492 (2019). PubMed: 31792210